Tysabri is a monoclonal antibody that helps treat autoimmune disorders such as MS and Crohn's disease.  The US Food and Drug administration (FDA) gave its approval for the drug first in November 2004.  Three months later it was pulled out of the market.  In November 2006 the FDA allowed the drug back on the market.  In January 2008 the FDA approved Tysabri for use in Crohn’s disease.

"Neurologists who have patients who report a family history of melanoma or have funny moles should send them to a dermatologist first. Don't just start them on drugs [Tysabri]," said Dr. John Thomas Mullen, co-author of the letter and a surgical oncologist with Beth Israel Deaconess Medical Center, in Boston. “And now that Tysabri has been approved for people with Crohn's disease, more people may be at risk, although those with no family history of melanoma and no moles probably don't need to worry,” Mullen said.

Patricia O'Looney, MD, vice president for biomedical research at the National Multiple Sclerosis Society says that there is not enough evidence to prove that Tysabri causes skin cancer.  "It is too early to even make a judgment of whether or not to give Tysabri to a patient with a family history of melanoma. The thing to do is to be aware of this possible risk and to go forward with caution."

Shannon Altimari, a spokesperson for Biogen Idec Inc., which in partnership with Elan Corp. markets Tysabri, has confirmed that another MS patient, a man who received treatment in clinical trials prior to the drug’s FDA approval, has also developed melanoma.

However, according to him, the manufacturers of the drug have no current plans of putting the caution notice on Tysabri's label warning doctors and patients of the possible risk of melanoma in patients with atypical moles or a family history of melanoma.

Source-Medindia
THK/L